Invivyd IVVD
NASDAQ IVVD
$0.83 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Invivyd (IVVD) Common Equity (2020 - 2026)

Invivyd's (IVVD) quarterly Common Equity came in at $181.1 million in Q2 2026, up 323.19% on a YoY basis from $42.8 million in Q2 2025, and down 25.03% quarter-over-quarter from $241.5 million in Q4 2025.

Analysis

Invivyd (IVVD) Common Equity (2020 - 2026) Analysis & Trends

Invivyd (IVVD) has reported Common Equity for 7 consecutive years, with $181.1 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Common Equity rose 323.19% year-over-year to $181.1 million; the trailing twelve-month figure through Jun 2026 stood at $181.1 million (up 323.19% YoY), and the FY2025 full-year result was $241.5 million, up 257.63% from the prior year.
  • Common Equity retreated to $181.1 million in Q2 2026 per IVVD's latest filing, from $241.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $459.4 million in Q1 2022 and bottomed at $42.8 million in Q2 2025.
  • Historically, Common Equity has averaged $219.0 million across 5 years, with a median of $181.1 million in 2026.
  • The sharpest annual moves came in 2022 and 2025: Common Equity soared 544.45% in 2022, then sank 69.66% in 2025.
  • Over 5 years, Common Equity stood at $356.0 million in 2022, then sank by 50.15% to $177.5 million in 2023, then slumped by 61.94% to $67.5 million in 2024, then soared by 257.63% to $241.5 million in 2025, then slipped by 25.03% to $181.1 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods registered $181.1 million, $241.5 million, and $93.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 11.69 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 11.83 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 20.25 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 31.71 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn 8.42 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn 6.76 Bn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 1.35 Bn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 18.85 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn 757.49 Mn
10 Invivyd 244.65 Mn 84.57 Mn 13.01 Mn 181.08 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 181.08 Mn
Dec 31, 2025 241.54 Mn
Sep 30, 2025 93.07 Mn
Jun 30, 2025 42.79 Mn
Mar 31, 2025 54.15 Mn
Dec 31, 2024 67.54 Mn
Sep 30, 2024 83.16 Mn
Jun 30, 2024 140.64 Mn
Mar 31, 2024 178.50 Mn
Dec 31, 2023 177.47 Mn
Sep 30, 2023 246.50 Mn
Jun 30, 2023 281.56 Mn
Mar 31, 2023 326.75 Mn
Dec 31, 2022 355.97 Mn
Sep 30, 2022 377.44 Mn
Jun 30, 2022 414.84 Mn
Mar 31, 2022 459.39 Mn
Dec 31, 2021 558.02 Mn
Sep 30, 2021 633.21 Mn
Jun 30, 2021 -144.62 Mn